ARTICLE | Management Tracks
Plus: BioLoomics hires Gish and an update from Beyond Air
By Richard Guy, Biopharma Analyst, and Gunjan Ohri, Data Content Analyst
June 14, 2024 9:50 PM UTC
Bioprocessing company Repligen Corp. (NASDAQ:RGEN) announced the transition of CEO Tony Hunt to executive chair, effective Sept. 1. President and chief commercial officer (CCO) Olivier Loeillot will become president and CEO, and current Chair Karen Dawes will transition to lead independent director. Loeillot, who will also join the company’s board, served as CEO of Ascensus Specialties LLC for nine months until June 2023.
BioLoomics Inc., which is developing antibody-peptide chimeras, hired Kurt Gish as CSO. Gish was CSO of Trilo Therapeutics Inc., a drug-conjugate company he founded. …
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/652725/new-ceo-for-repligen-as-hunt-moves-to-executive-chair